Methyl 2-Oxoindoline-6-Carboxylate CAS 14192-26-8 Tsarkake>99.0% (HPLC) Nintedanib Esylate Intermediate Factory

Takaitaccen Bayani:

Sunan Kemikal: Methyl 2-Oxoindoline-6-Carboxylate

Saukewa: 14192-26-8

Tsafta:> 99.0% (HPLC)

Bayyanar: Rawaya mai haske zuwa launin ruwan kasa

Matsakaici na Nintedanib Esylate (CAS: 656247-18-6) a cikin maganin ciwon huhu mara ƙananan ƙwayar cuta & fibrosis na huhu na idiopathic (IPF)

Kyakkyawan inganci, Samar da Kasuwanci

E-Mail: alvin@ruifuchem.com


Cikakken Bayani

Samfura masu dangantaka

Tags samfurin

Bayani:

Shanghai Ruifu Chemical Co., Ltd. shine babban masana'anta kuma mai ba da kayayyaki na Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) tare da babban inganci, samar da kasuwanci.

Abubuwan Sinadarai:

Sunan Sinadari Methyl 2-Oxoindoline-6-Carboxylate
Makamantu 2-Oxoindoline-6-Carboxylic Acid Methyl Ester;Methyl Oxindole-6-Carboxylate
Lambar CAS 14192-26-8
Lambar CAT Saukewa: RF-PI1524
Matsayin Hannun jari A cikin Hannun jari, Ma'aunin samarwa Har zuwa Ton
Tsarin kwayoyin halitta Saukewa: C10H9NO3
Nauyin Kwayoyin Halitta 191.19
Matsayin narkewa 184.0 ~ 190.0 ℃
Alamar Ruifu Chemical

Ƙayyadaddun bayanai:

Abu Ƙayyadaddun bayanai
Bayyanar Rawaya Mai Haske zuwa Foda Brown
1 H NMR Spectrum Daidaita Da Tsarin
Tsarkake / Hanyar Bincike > 99.0% (HPLC)
Asara akan bushewa <1.00%
Jimlar ƙazanta <1.00%
Matsayin Gwaji Matsayin Kasuwanci
Amfani Matsakaicin Nintedanib Esylate (CAS: 656247-18-6)

Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) Hanyar roba

CAS

Kunshin & Ajiya:

Kunshin: Bottle, Aluminum tsare jakar, 25kg / Kwali Drum, ko bisa ga abokin ciniki ta bukata.

Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi.

Amfani:

1

FAQ:

Aikace-aikace:

Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) matsakaici ne da ake amfani dashi don shirya Nintedanib Esylate (CAS: 656247-18-6).Nintedanib Esylate mai ƙarfi ne, mai hanawa na baka sau uku angiokinase wanda Boehringer Ingelheim ya haɓaka wanda ke yin niyya ta hanyoyin proangiogenic da pro-fibrotic waɗanda ke shiga tsakani ta hanyar mai karɓar haɓakar haɓakar jijiyar jijiyoyi, mai karɓar haɓakar haɓakar fibroblast da plateletderived girma factor iyalai, kazalika da Src da Flt-3 kinase.An amince da Nintedanib Esylate don maganin fibrosis na huhu na huhu (IPF), yanayin da huhu ke ci gaba da raguwa a cikin lokaci, ta hanyar FDA ta Amurka a watan Oktoba 2014 da EMA a cikin Janairu 2015. FDA ta ba da nintedanib esylate mai sauri-track. , Bita na fifiko, samfuran marayu, da nadi na ƙima.EMA kuma ta amince da ita a watan Nuwamba 2014 don maganin ciwon huhu mara ƙananan ƙwayoyin cuta a hade tare da docetaxel bayan layin farko na chemotherapy.

Ku rubuta sakonku anan ku aiko mana